Factors correlated with the improvement of endothelial dysfunction during Abatacept therapy in patients with rheumatoid arthritis

Figures & data

Table 1 Significant comparison between baseline and follow-up parameters analyzed before and after treatment with Abatacept in RA patients

	T0	T1	p-statistics
ESR	29.82 (1.9), 25.99–33.65	21.07 (2.2), 16.51–25.63	0.0002 (MW)
CRP	1.37 (0.1), 1.04–1.70	0.83 (0.12), 0.57–1.1	0.0023 (MW)
DAS28	3.79 (0.10), 3.57–4	2.89 (0.15), 2.59–3.20	<0.0001 (TT)
IL-6	10.22 (2.08), 6.01–14.43	4.02 (0.37), 3.25–4.78	<0.0001 (TT)

Note: Values are expressed in mean, SEM, and 95% CI.

Abbreviations: CRP (mg/dL), C-reactive protein; DAS28, disease activity 28 score; ESR (mm/h), erythrocyte sedimentation rate; IL-6 (pg/mL), interleukin-6; MW, Mann–Whitney test; RA, rheumatoid arthritis; SEM, standard error mean; TT, Student’s t-test.

Table 2 Significant correlation of FMD and ccIMT at baseline (T0) and at 1 year follow-up (T1) with other parameters at T0 and T1, respectively

		FMD T0	ccIMT T0	FMD T1	ccIMT T1
		5.52 (0.04), 5.42–5.61	0.77 (0.01), 0.74–0.80	5.604 (0.04), 5.50–5.70	0.74 (0.001), 0.71–0.77
CRP (mg/dL) T0	1.37 (0.1), 1.04–1.70	Not significant	Not significant	–	–
CRP T1	0.83 (0.12), 0.57–1.1	–	–	p=0.0075	Not significant
TNFα T0	21.49 (3.6), 14.14–28.84	Not significant	p=0.02	–	–
TNFα T1	25.80 (6.09), 6.01–14.43	–	–	Not significant	p=0.02
CD3/CD8+T0	514.3 (42.6), 428.5–600.2	Not significant	Not significant	–	–
CD3/CD8+T1	500.2 (35.53), 428.6–571.9	–	–	Not significant	p=0.03

Note: Values are expressed in mean, SEM, and 95% CI.

Abbreviations: CRP (mg/dL), C-reactive protein; FMD, flow-mediated dilation; SEM, standard error mean; TNFα (pg/mL), tumor necrosis factor alpha; ccIMT, common carotid intima media thickness.